of 1 /1
PATENT ABSTRACTS 311 The genomes of the mutants differ from the genomes of the parent strain by the presence of one or more deletions selected from a deletion in the inverted repeats, a deletion in the unique sequence, and a deletion in the thymidine kinase gene. The new deletion mutants are avirulent, do not induce latent infections, are stable and poss- ess good immunogenic properties. The invention also relates to vaccines containing the new mutant strains. and a segment derived from a broad host range plasmid. The broad host range plasmid segment includes Mob-functions and DNA coding for replication functions with regions non-essential for broad host range replication or mobilizablity having been deleted. Bacterial strains containing the above plasmids as well as methods of cloning DNA employing such plasmids are also pro- vided. 4680260 METHOD FOR PRODUCING HUMAN LEUKOCYTE INTERFERON ALPHA-2 Vladimir G Debabov, Jury Tsygankov, Andrei J Chistoserdov, Evgeny Sverdlov, Lara S Izotova, Sergei Kostrov, Viktor Sterkin, Vladimir P Kuz- netsov, Sergei Belyaev, Galina S Monastyr- skaya, Irina Salomatina, Grigory Dolganov, Sergei Arsenian, Sergei A Tsarev, Jury Kozlov, Alexandr Y Strongin, Vsevolod I Ogarkov, Jury A Ovchinnikov, Moscow, Union Of Soviet Socialist Republics assigned to Vsesojuzny Nauchno-Issledovatelsky Institut Genetiki A method for producing human leukocyte inter- feron alpha-2 resides in that there is carried out submerged cultivation of a producer strain Pseudomonas species VG-84 carrying a plasmid pVG3 with an inserted gene of human leukocyte interferon alpha-2, said strain being deposited in the collection of microorganism cultures at the USSR Antibiotics Research Institute under Reg. No. 1742; said strain being cultivated in a nutr- ient medium, containing the sources of carbon and nitrogen, mineral salts and growth stimulants, under aeration in the presence of antibiotics, i.e., streptomycin or tetracycline, or a mixture of both, followed by isolation and purification of the end product. 4680264 CLASS II MOBILIZABLE GRAM- NEGATIVE PLASMID Alfred Puhler, Reinhard Simon, Ursula Priefer, Bielefeld. Federal Republic Of Germany as- signed to Lubrizol Genetics Inc Vectors capable of replication in a broad host range of gram-negative bacteria are provided. The vectors are composite plasmids comprising a segment derived from an E. coli vector plasmid 4680265 METHOD OF SELECTING RECOMBINANT DNA- CONTAINING STREPTOMYCES Virginia A Birmingham, Eugene T Seno as- signed to Eli Lilly and Company A novel method of selecting Streptomyces recombinant DNA-containing host cells and vectors useful in the method are described. The vectors confer tylosin resistance to sensitive Streptomyces host cells and thus provide a con- venient method of selecting Streptomyces trans- formants. The novel tylosin resistance- conferring gene described can be isolated on an £18 2.6 kb Kpnl restriction fragment from plas- mid pSVB2. Plasmid pSVB2 can be isolated from + I Streptomyces lividans + L TK23/pSVB2 (NRRL 15880). 4681762 GENETICALLY ATTENUATED BACTERIAL VACCINES WITH MULTIPLE MUTATIONS OF THE SAME PHENOTYPE Max P Oeschger, Anne Hooke, Joseph A Bel- lanti assigned to Research Corporation The present invention relates to a vaccine com- position for the prevention of infectious diseases comprising an immunogenically-effective amount of a genetically attenuated and stable avirulent bacterial strain derived from a virulent bacterial strain by introducing into said virulent strain by genetic transfer and recombination at least two mutations of the same phenotype which renders said virulent strain avirulent, while permitting said avirulent strain to retain immunogenicity, together with an inert pharma- cologically acceptable carrier. It also relates to a method for preparing the vaccine.

4680264 Class II mobilizable gram-negative plasmid

Embed Size (px)

Citation preview

Page 1: 4680264 Class II mobilizable gram-negative plasmid

PATENT ABSTRACTS 311

The genomes of the mutants differ from the genomes of the parent strain by the presence of one or more deletions selected from a deletion in the inverted repeats, a deletion in the unique sequence, and a deletion in the thymidine kinase gene. The new deletion mutants are avirulent, do not induce latent infections, are stable and poss- ess good immunogenic properties. The invention also relates to vaccines containing the new mutant strains.

and a segment derived from a broad host range plasmid. The broad host range plasmid segment includes Mob-functions and DNA coding for replication functions with regions non-essential for broad host range replication or mobilizablity having been deleted. Bacterial strains containing the above plasmids as well as methods of cloning DNA employing such plasmids are also pro- vided.

4680260

M E T H O D F O R P R O D U C I N G H U M A N L E U K O C Y T E

I N T E R F E R O N A L P H A - 2

Vladimir G Debabov, Jury Tsygankov, Andrei J Chistoserdov, Evgeny Sverdlov, Lara S Izotova, Sergei Kostrov, Viktor Sterkin, Vladimir P Kuz- netsov, Sergei Belyaev, Galina S Monastyr- skaya, Irina Salomatina, Grigory Dolganov, Sergei Arsenian, Sergei A Tsarev, Jury Kozlov, Alexandr Y Strongin, Vsevolod I Ogarkov, Jury A Ovchinnikov, Moscow, Union Of Soviet Socialist Republics assigned to Vsesojuzny Nauchno-Issledovatelsky Institut Genetiki

A method for producing human leukocyte inter- feron alpha-2 resides in that there is carried out submerged cultivation of a producer strain Pseudomonas species VG-84 carrying a plasmid pVG3 with an inserted gene of human leukocyte interferon alpha-2, said strain being deposited in the collection of microorganism cultures at the USSR Antibiotics Research Institute under Reg. No. 1742; said strain being cultivated in a nutr- ient medium, containing the sources of carbon and nitrogen, mineral salts and growth stimulants, under aeration in the presence of antibiotics, i.e., streptomycin or tetracycline, or a mixture of both, followed by isolation and purification of the end product.

4680264

C L A S S II M O B I L I Z A B L E G R A M - N E G A T I V E P L A S M I D

Alfred Puhler, Reinhard Simon, Ursula Priefer, Bielefeld. Federal Republic Of Germany as- signed to Lubrizol Genetics Inc

Vectors capable of replication in a broad host range of gram-negative bacteria are provided. The vectors are composite plasmids comprising a segment derived from an E. coli vector plasmid

4680265

M E T H O D O F S E L E C T I N G R E C O M B I N A N T D N A -

C O N T A I N I N G S T R E P T O M Y C E S

Virginia A Birmingham, Eugene T Seno as- signed to Eli Lilly and Company

A novel method of selecting Streptomyces recombinant DNA-containing host cells and vectors useful in the method are described. The vectors confer tylosin resistance to sensitive Streptomyces host cells and thus provide a con- venient method of selecting Streptomyces trans- formants. The novel tylosin resistance- conferring gene described can be isolated on an £18 2.6 kb Kpnl restriction fragment from plas- mid pSVB2. Plasmid pSVB2 can be isolated from + I Streptomyces lividans + L TK23/pSVB2 (NRRL 15880).

4681762

G E N E T I C A L L Y A T T E N U A T E D B A C T E R I A L V A C C I N E S W I T H

M U L T I P L E M U T A T I O N S O F T H E S A M E P H E N O T Y P E

Max P Oeschger, Anne Hooke, Joseph A Bel- lanti assigned to Research Corporation

The present invention relates to a vaccine com- position for the prevention of infectious diseases comprising an immunogenically-effective amount of a genetically attenuated and stable avirulent bacterial strain derived from a virulent bacterial strain by introducing into said virulent strain by genetic transfer and recombination at least two mutations of the same phenotype which renders said virulent strain avirulent, while permitting said avirulent strain to retain immunogenicity, together with an inert pharma- cologically acceptable carrier. It also relates to a method for preparing the vaccine.